One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma

Ipsen54 enrolled

Overview

This non-interventional retrospective study aims to describe the therapeutic procedures and modalities received by patients and the correlation to hormone status, during a one year follow up from completion of the 2-79-52030-207 study.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Acromegaly

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Completed the 2-79-52030-207 study and received 12 injections of lanreotide Autogel 120 mg, regardless of efficacy at the end of this period. * Subject or in case of subject's death next of kin having given their written informed consent prior to collection of the data by the sponsor (if locally required)

Locations (18)

III. Interní klinika Karlova Univerzita

Prague, Czechia

CHU de Rouen

Bois-Guillaume, France

Groupement hôspitalier est Federation d'endocrinologie.

Outcomes

Primary Outcomes

Proportion of patients maintained on medical treatment with lanreotide Autogel

Time frame: 1 year

Proportion of patients receiving other medical treatments

Time frame: 1 year

Secondary Outcomes

Proportion of patients with at least one pituitary surgery

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.